Atomic AI, Inc. is a well-funded, early-stage biotech company transforming the rational design of molecules and medicines through the cutting-edge fusion of artificial intelligence and structural biology. Atomic’s unique R&D platform provides new strategies to treat or cure previously-undruggable diseases by targeting RNA structure. We are an interdisciplinary team working across computational and experimental biology and believe that our strongest asset is our people. Here is a link to an article about Atomic AI's unique R&D platform featured on the cover of Science: doi.org/10.1126/science.abe5650